Transaction type: Reverse Transaction
Operation type:Liquidity providing
Tender date:JUL-09-2020
Time for submission of bids14.00-14.30 (CEST)
Start date:JUL-13-2020
Maturity date:OKT-05-2020
Duration:84 days
Offered volume:10.0 bln 
Min bid amount: 100 mln
Maximum bid amount: 4.0 bln
Max number of bids:10
Lowest interest supplement:0.25 percentage points
Min bid rate:0.32 %
Allocation time:15.00 (CEST) on Tender date

Approved counterparties are invited to submit bids to the Riksbank, tel +46 8 6966970 by 14.30 (CEST) pm on Jul 9, 2020.
Confirmation of bids to e-mail:

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Kommuniké från extra bolagsstämma i Active Biotech samt justering av tidigare kommunicerad tidplan avseende nyemissionen30.11.2020 15:30:00 CETPressemelding

Extra bolagsstämma i Active Biotech AB (publ) hölls den 30 november 2020. Stämman beslutade, i enlighet med styrelsens förslag, om nyemission med företrädesrätt för aktieägarna. Genom nyemissionen ges högst 72 618 240 nya aktier ut. Två befintliga aktier berättigar till teckning av en ny aktie. Nyemissionen omfattas av vederlagsfria teckningsåtaganden och emissionsgarantier om cirka 40,0 miljoner kronor. Teckningskursen uppgår till 1,05 kronor per aktie. Avstämningsdag för rätt att delta i nyemissionen är den 4 januari 2021. Teckning av de nya aktierna ska ske under perioden 7 – 21 januari 2021. Ett prospekt avseende nyemissionen kommer att offentliggöras före teckningsperiodens början. Preliminär tidplan Sista dag för handel i Active Biotech-aktien inklusive rätt att delta i emissionen infaller den 29 december 2020, istället för den 30 december 2020 som tidigare har kommunicerats. 30 november 2020Extra bolagsstämma 29 december 2020Sista dag för handel i Active Biotech-aktien inklusive

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue30.11.2020 15:30:00 CETPress release

An extraordinary general meeting of Active Biotech was held on November 30, 2020. The meeting resolved, in accordance with the board’s proposal, on a new share issue with pre-emptive rights for existing shareholders. Through the rights issue, not more than 72,618,240 new shares are issued. Two existing shares entitle to subscription for one new share. The rights issue is covered by free of charge subscription commitments and issue guarantees of approximately SEK 40.0 million. The subscription price amounts to SEK 1.05 per share. The record date for participation in the rights issue is January 4, 2021. Subscription for the new shares shall be made during the period 7 – 21 January 2021. A prospectus regarding the rights issue will be made public prior to the commencement of the subscription period. Preliminary timetable Last day for trading in the Active Biotech share including the right to participate in the rights issue is December 29, 2020, instead of December 30, 2020 as previously c

ITCL - Annual General Meeting 202030.11.2020 15:18:40 CETPress release

Independent Tankers Corporation Limited (the "Company") advises that the 2020 Annual General Meeting of the Company will be held on December 23, 2020. The record date for voting at the Annual General Meeting is set to December 2, 2020. The notice, agenda and associated material will be distributed prior to the meeting. Hamilton, Bermuda November 30, 2020 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Bombardier Appoints Bart Demosky Executive Vice President and Chief Financial Officer30.11.2020 14:55:00 CETPress release

MONTREAL, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) announced today the appointment of Bart Demosky as Executive Vice President and Chief Financial Officer, effective immediately. Bart will report to Éric Martel, President and Chief Executive Officer, Bombardier Inc., replacing John Di Bert who will be leaving the Company. “We are very excited to welcome Bart to the Bombardier leadership team,” said Éric Martel. “He is an accomplished leader with broad financial experience and an impressive track record of success at some of Canada’s largest corporations. Bart’s deep knowledge and expertise in all aspects of corporate finance will serve us well as we complete our strategic repositioning to a leaner, more focused company. I’m confident that Bart will provide strong leadership as we manage through the current economic challenges and continue to position Bombardier for the future.” Bart brings over 30 years of experience leading organizational transformations and building

Interim Results for the Period Ended September 30, 202030.11.2020 13:46:38 CETPress release

Highlights and subsequent events Golar LNG Partners LP (“Golar Partners” or “the Partnership”) generated operating income of $32.1 million for the third quarter of 2020, exclusive of its interest in FLNG Hilli Episeyo.After accounting for $1.1 million of non-cash mark-to-market interest rate swap losses, the Partnership reported net income attributable to unit holders of $17.4 million for the third quarter.The Partnership generated distributable cash flow1 of $20.7 million for the third quarter resulting in a distribution coverage ratio1 of 14.50.The Partnership entered into a cooperation agreement with Hygo Energy Transition Limited ("Hygo"), formerly known as Golar Power Limited, to develop terminals using Golar Partners' asset portfolio.Increased utilization of the carrier Golar Maria helped lift the Partnership's overall fleet utilization to 98% for the quarter.The Partnership declared a distribution for the third quarter of $0.0202 per unit. Financial Results Overview Golar Partne